Cell line · CVCL_0359
J82
Cancer cell line, Homo sapiens. Bladder carcinoma. 68 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Download JSON
Cite this record
ConductScience Library. J82. Cell lines, record CVCL_0359. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_0359
On this page
Cell line
As Cellosaurus gives it.
- Name
- J82
- Accession
- CVCL_0359
- RRID
- RRID:CVCL_0359
- Synonyms
- J-82, J 82, J82COT, J82 COT, J82 CO'T, J82/WT
- Species
- Homo sapiens (Human)
- Sex
- Male
- Age at sampling
- 58Y
- Category
- Cancer cell line
- Diseases
- Bladder carcinoma (NCIt C4912)
- Derived from
- Urinary bladder (in situ)
- Entry created
- 2012-04-04
- Entry updated
- 2026-06-25
Source Cellosaurus
Problems0
Cellosaurus records no problem for this cell line.
None in this release.
Papers68
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Investigation of the significance and role of androgen receptor expression in basal/squamous type urothelial carcinoma cell line J82 cells. | BMC Cancer | 2026 | Its Methods give the RRID and name the line | PubMed | |
| ZW4864-mediated inhibition of the β-catenin/BCL9/BCL9L complex reveals therapeutic potential in bladder cancer. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| O-GlcNAcylated TAP1 Impairs Antigen Presentation and Promotes Immune Evasion in Bladder Cancer. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| TIMP1 Derived from Mesenchymal Stem Cells Promotes Bladder Cancer Progression by Regulating the Formation of VDIMs through the RAP1 Pathway. | Int J Biol Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Combining 5-ALA-PDT with berbamine as an in vitro multimodal therapy approach against bladder cancer cells. | Sci Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| m5C-Modified tRF3b-CysGCA-23 Suppresses Bladder Cancer Malignancy by Repressing H3K18 Lactylation via Stabilizing RBM4. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Therapeutic strategies for MMAE-resistant bladder cancer through DPP4 inhibition. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| piR-43452 suppresses bladder cancer progression and enhances gemcitabine sensitivity via GTSF1/PIWIL4-mediated LRP1 mRNA destabilization. | Transl Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Histone deacetylase HDAC7 restricts CD8 + T cell tumor infiltration and limits immunotherapy sensitivity in bladder cancer: reversal by pinocembrin. | J Exp Clin Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed |
1 to 10 of 68
See all 68 papersRelatives4
| Relation | Cell line | Accession | Problem | Source |
|---|---|---|---|---|
| Derived from it | Hu609 | CVCL_8240 | Has a recorded problem | Cell lines |
| Derived from it | J82-NVB | CVCL_4V98 | Cell lines | |
| Derived from it | J82/MMC | CVCL_C8D4 | Cell lines | |
| From the same person | J82-EBV | CVCL_5H97 | Cell lines |
Cell banks6
| Cell bank | Catalog number | Status | Source |
|---|---|---|---|
| ATCC | HTB-1 | ATCC | |
| CCTCC | GDC0225 | Cellosaurus | |
| CLS | 305055 | CLS | |
| Hysigen | TCH-C221 | Hysigen | |
| KCB | KCB 2014052YJ | Cellosaurus | |
| KCLB | 30001 | KCLB |
Data dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0359
GET https://conductscience.org/api/cell-lines/v1/CVCL_0359/papers?page=2